1Droller MJ.Bladder cancer:state-of-the-art care.CA Cancer J Clin,1998,48,269～284
2Jeffrey SR,Jonathan AF.HER-2/neu(C-erbB-2)gene and protein in breast cancer.Am J Clin Pthol,1999,112(sup),s53
3Karunagaran D,Tzahar E,Beerli RR,et al.ErbB-2 is a common auxiliary subunit of NDF and EGF receptors:implications for breast cancer.EMBO J,1996,15,254～264
5Joensuu H,Isola J,Lundin M,et al.Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer:a nationwide population-based study.Clin Cancer Res,2003,9,923～930
6Hayes DF,Thor AD.c-erbB-2 in breast cancer:development of a clinically useful marker.Semin Oncol,2002,29,231～245
7Paik S,Tan-chui E,Bryan J,et al.Successful quality assurance program for HER-2 testing in the NSABP trial for Herceptin.Breast Cancer Res Treat,2002,76(suppl 1),S31
8Zhao J,Wu R,Au A,et al.Determination of HER2 gene amplification by chromogenic in situ hybridization(CISH) in archival breast carcinoma.Mod Pathol,2002,15,657～665
9El-Ahmady O,El-Salahy E,Mahmoud M,et al.Multivariate analysis of bcl-2,apoptosis,P53 and HER-2/neu in breast cancer:a short-term follow-up.Anticancer Res,2002,22,2493～2499
10Jensen B,Johansen J,Price P.High.Levels of Serum HER-2/neu and YKL-40 Independently Reflect Aggressiveness of Metastatic Breast Cancer.Clin Cancer Res,2003,9(12),4423～4434
4Shipley WU, Zielman AL, Kaufman DS, et al. Selective bladder preservation by trimodality therapy for patients with muscularis propria-invasive bladder cancer and who are cystectomy candidates-the Massachusetts general hospital and Radiation Therapy Oncology Group experiences [ J ] . Semin Radiat Oneol, 2004, 15(1): 36-41
5Vollmer RT, Humphrey PA, Swanson PE,et al. Invasion of the bladder by transitional cell carcinoma its relation to histologic grade and expression of P53, MIB-1, c-erb B-2, epidermal growth factor receptor, and Bcl-2 [ J ] . Cancer, 1998, 82(5): 715-723.
6Hussain SA, Ganesan R, Hiller L, et al. Bcl-2 expression predicts survival in patients receiving synchronous chemoradiotherapy in advanced transitional cell carcinoma of the bladder [ J ].Oncol Rep, 2003, 10(3): 571-576.
7Cooke PW, James ND, Ganesan R, et al. Bcl-2 expression identifies patients with advanced bladder cancer treated by radiotherapy who benefit from neoadjuvant chemotherapy [ J ] . BJU Int, 2000, 85(7): 829-835.
8Tsai YS, Tzai TS, Chow NH, et al. Does Her-2 immunoreactivity provide prognostic information in locally advanced urothelial carcinoma patients receiving adjuvant M-VEC chemotherapy? [ J ] . Urol Int, 2007, 79(1): 210- 216.
9Rotterud R, Berner A, Holm R, el al. P53, p21 and mdm2 expression vs the response to radiotherapy in transitional cell carcinoma of the bladder [ J ] . Bju Int, 2001, 88(3): 202- 208.
10Ribeiro JC, Barnetson AR, Fisher RJ, et al. Relationship between radiation response and P53 status in human bladder cancer cells [ J ] . Int J Radiat Biol, 1997, 72(1): 11-20.
